Chronic Obstructive Pulmonary Disease Treatment Devices Market

Global chronic obstructive pulmonary disease (COPD) treatment devices market is estimated to grow at a CAGR of 6.37% during the forecast period from 2023 to 2028.

The increase in demand for chronic obstructive pulmonary disease treatment devices is primarily attributed to the rising exposure to air pollution, airborne particles, chemicals & fumes, secondhand smoke, industrial chemicals and dust owing to which the prevalence of COPD is increasing globally. Further, rise in consumption of tobacco among youth population will increase the risk of respiratory disorders like COPD, asthma ultimately leading to propel the demand of COPD treating devices. Additionally, the burgeoning demand for short-term and effective treatment in case of attacks, technological advancements in the devices such as production of ideal aerosol particle size & property of providing higher amount of dose, and others, and increasing awareness about the symptoms and treatment of disorders like COPD and asthma across the world are anticipated to bolster the market, thereby contributing to the growth of the chronic obstructive pulmonary disease treatment devices market during the forecast period from 2023-2028.

Some of the key market players operating in the Chronic Obstructive Pulmonary Disease Treatment Devices market include Koninklijke Philips N.V. (PHG), Omron Healthcare, Inc. (OMRNY), Aerogen, PARI GmbH, GF Health Products, Inc., BMC Medical Co., Ltd., Medtronic PLC (MDT), Invacare Corporation (NYSE: IVC), Trudell Medical International, Nouvag AG, Timesco Healthcare Ltd., LAICA S.p.A., Vega Technologies Inc., Besco Medical Limited, DeVilbiss Healthcare LLC, Feellife Health Inc., Wellinks, Rossmax International Ltd., Novartis AG (NVS), AstraZeneca (AZN), GlaxoSmithKline plc (GSK), Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, LepuMedical Technology(Beijing)Co.,Ltd., Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc. (NSE: CIPLA), Microlife Corporation, Honsun, and others.

DelveInsight’s “Chronic Obstructive Pulmonary Disease Treatment Devices Market Insight & Forecast” report will offer an in-depth understanding of the Chronic Obstructive Pulmonary Disease Treatment Devices market, further benefiting the competitors or stakeholders operating in the Chronic Obstructive Pulmonary Disease Treatment Devices arena.

Chronic Obstructive Pulmonary Disease Treatment Devices Overview

Chronic obstructive pulmonary disease treatment devices are the medical devices or tools used by a patient to treat the symptoms of chronic obstructive pulmonary disease. The medication to treat COPD is administrated through a device such as inhalers, used to get relief from the symptoms of the disease.

Interested in knowing more about the functioning of Chronic Obstructive Pulmonary Disease Treatment Devices- Visit @ Chronic Obstructive Pulmonary Disease Treatment Devices Operations & Working.

Chronic Obstructive Pulmonary Disease Treatment Devices Market Insights

North America is expected to account for the largest share of the global Chronic Obstructive Pulmonary Disease Treatment Devices market. The growing prevalence of chronic obstructive pulmonary disease due to exposure to air pollution, airborne particles, chemicals & fumes, secondhand smoke, industrial chemicals & dust, and a rise in the consumption of tobacco among the youth population will drive the demand for chronic obstructive pulmonary disease treatment devices in the forecast period. Further, government initiations to create awareness of diagnosis and treatment of COPD, leading to increased demand for treatment devices in the market. This led to a growth in the North American chronic obstructive pulmonary disease treatment devices market growth.

For instance, according to the Center for Disease Control and Prevention (CDC) 2020, it was estimated that the percentage of COPD, emphysema, or chronic bronchitis for adults aged 18 and over in the United States in the year 2020 was 5.0%. Moreover, according to Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Report 2022, reported that the prevalence of COPD is higher in smokers & ex-smokers as compared to non-smokers in the United States. The morbidity of COPD may be affected by other chronic diseases such as cardiovascular diseases, musculoskeletal impairment, diabetes, and others related to smoking, age, and genetics. Additionally, as per CDC 2020, the number of deaths in the year 2020 due to bronchitis was nearly 457 in the US. Further, emphysema deaths in the year 2020 in the US were nearly 7,425. The increasing prevalence and mortality rate can be slowed down by giving proper treatment to the patients by using the treatment devices such as inhalers and nebulizers, ultimately leading to an increased demand for COPD treating devices. Thus, the increasing prevalence of COPD in the United States is anticipated to bolster the COPD treatment devices market in the forecast period, thereby increasing the overall market growth in North America.

Furthermore, according to the United States Environmental Protection Agency 2021, in the year 2021, it was calculated that about 67 million tons of pollution were emitted into the atmosphere in the United States. Breathing in air pollutants can irritate the airways and may cause shortness of breath, coughing, and wheezing. People with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) are vulnerable to the detrimental effects of air pollutants. Air pollution can induce the acute exacerbation of COPD and can increase respiratory morbidity and mortality. The increasing air pollution may increase the incidence and exacerbation of COPD, leading to the increased demand for COPD treating devices like inhalers and nebulizers in the market. Thus, increasing the market of the devices in the forecast period 2022-2027. Therefore, propelling the overall market growth of chronic obstructive pulmonary disease treatment devices in North America.

Thus, all the above-mentioned factors will collectively contribute to the chronic obstructive pulmonary disease treatment devices market growth in the North American region.

To read more about why North America is leading the market growth in the Chronic Obstructive Pulmonary Disease Treatment Devices market, get a snapshot of the Chronic Obstructive Pulmonary Disease Treatment Devices market report.

Chronic Obstructive Pulmonary Disease Treatment Devices Market Dynamics

The chronic obstructive pulmonary disease treatment devices market is witnessing a growth in product demand for various reasons, such as the growing prevalence of COPD due to long-term exposure to air pollution, secondhand smoke, dust, fumes, and chemicals. Furthermore, the rise in tobacco consumption among the youth population is anticipated to bolster the market for chronic obstructive pulmonary disease treatment devices during the forecast period.

For instance, according to the data published by World Health Organization (WHO) 2022, it was estimated that COPD was the third leading cause of death worldwide, causing 3.23 million deaths in the year 2019. Additionally, nearly 90% of COPD deaths were those in patients under 70 years of age in low- and middle-income countries. Moreover, COPD causes persistent and progressive respiratory symptoms, including difficulty in breathing, cough, and phlegm production. The disorder results from long-term exposure to harmful gases and particles combined with individual factors, including events that influence lung growth in childhood and genetics. Early diagnosis and treatment, including smoking cessation support, is required to slow down the incidence and mortality rate of the disease. However, the increasing prevalence of COPD will increase the demand for treatment devices such as inhalers and nebulizers, thereby expected to propel the overall market growth of COPD treatment devices in the forecast period of 2022 – 2027.

Moreover, according to the American Lung Association, State of Tobacco Control 2022, a 2021 study found that menthol cigarettes were responsible for 1.5 million new smokers among African Americans in 2021. The study concluded that from 2019 to 2021, disposable e-cigarette use skyrocketed by more than 23 times among high school e-cigarette users (from 2.4% to 55.8%) and more than 14 times among middle school e-cigarette users (from 3% to 43.8%). Additionally, according to National Youth Tobacco Survey 2020, it was estimated that in 2019-2020 more than 23.6% of high school students in the U.S. use at least one tobacco product, including e-cigarettes. As per the same source, smoking is the number one preventable cause of death in the U.S., killing over 480,000 people annually. Furthermore, COPD is usually caused by cigarette smoking, though long-term exposure to other lung irritants, like secondhand smoke, can also contribute to COPD. Smoking damages the air sacs, airways, and the lining of the lungs, making it sensitive to COPD and other respiratory disorders. Smoking is also a trigger for COPD flare-ups. Injured lungs have trouble moving enough air in and out, so it’s hard to breathe; one of the major symptoms of COPD. Moreover, exposure to secondhand smoke during childhood and teenage years can slow lung growth and development. The rising consumption of smoking globally will increase the prevalence of COPD, leading to the surging demand for the treatment devices, ultimately bolstering the overall market growth of COPD treating devices.

However, the high cost of chronic obstructive pulmonary disease treatment devices, stringent government regulations, and environmental concerns associated with metered dose inhalers (MDI) may limit the growth of chronic obstructive pulmonary disease treatment devices.

Covid 19 Impact Analysis

The ongoing COVID-19 pandemic had a drastic positive impact on the chronic obstructive pulmonary disease treatment devices market owing to the rising burden of respiratory diseases in the COVID-19 pandemic as the viral infection severely affects the lungs. Moreover, it is estimated that people may develop a respiratory illness such as COPD and others as an aftereffect, which will surge the demand for the devices among COVID recovering patients. However, due to strict lockdown restrictions, there was a disruption in the supply chain leading to the unavailability of raw materials and halting the manufacturing process. This led to a shortage of devices and higher prices of devices in the market. However, with the masses being vaccinated, and resumption of the cross-border trade and supply chain, and the increasing demand, the key players in the chronic obstructive pulmonary disease treatment devices market increased their manufacturing across the world are anticipated to bolster the market, thereby contributing to the growth of the chronic obstructive pulmonary disease treatment devices market during the forecast period from 2022-2027.

Recent Breakthroughs in Chronic Obstructive Pulmonary Disease Treatment Devices Market:

• In August 2021, Lupin Healthcare Limited, a wholly-owned subsidiary of global pharma major Lupin Limited, announced that the Medicines and Healthcare products Regulatory Agency (MHRA) had approved its Luforbec® (beclometasone/formoterol) 100/6 dose pressurized metered dose inhaler (pMDI) for the patients in the UK. Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD).
• In January 2021, Wellinks, the nebulizer’s developer, announced that the wireless nebulizer for use by people with chronic obstructive pulmonary disease (COPD) had been cleared by a review board of the U.S. Food and Drug Administration (FDA).
• In October 2020, Zydus Cadila, an Indian multinational pharmaceutical company, announced that they had launched Forglyn pMDI, a Pressurized Metered Dose Inhaler (pMDI) with a combination of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting Beta Agonist (LABA) for patients suffering from Chronic Obstructive Pulmonary Disease (COPD) in India.
• In July 2020, AstraZeneca’s, a global, science-led biopharmaceutical company, announced that its Breztri Aerosphere inhaler has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Key Players Proactively Working In the Chronic Obstructive Pulmonary Disease Treatment Devices Market

Key Chronic Obstructive Pulmonary Disease Treatment Devices companies involved in manufacturing and production are making significant growth in the advancement of these devices. To boost their market position, they also engage in mergers and acquisitions. Some of the key Chronic Obstructive Pulmonary Disease Treatment Devices companies operating actively in the chronic obstructive pulmonary disease treatment devices market include Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, PARI GmbH, GF Health Products, Inc., BMC Medical Co., Ltd., Medtronic PLC, Invacare Corporation, Trudell Medical International, Nouvag AG, Timesco Healthcare Ltd., LAICA S.p.A., Vega Technologies Inc., Besco Medical Limited, DeVilbiss Healthcare LLC, Feellife Health Inc., Wellinks, Rossmax International Ltd., Novartis AG, AstraZeneca, GlaxoSmithKline plc, Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, LepuMedical Technology(Beijing)Co., Ltd., Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc., Microlife Corporation, Honsun, and others.

Scope of the Chronic Obstructive Pulmonary Disease Treatment Devices Market Report:

• Geography Covered: Global
• Key Chronic Obstructive Pulmonary Disease Treatment Devices Companies: Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, PARI GmbH, GF Health Products, Inc., BMC Medical Co., Ltd., Medtronic PLC, Invacare Corporation, Trudell Medical International, Nouvag AG, Timesco Healthcare Ltd., LAICA S.p.A., Vega Technologies Inc., Besco Medical Limited, DeVilbiss Healthcare LLC, Feellife Health Inc., Wellinks, Rossmax International Ltd., Novartis AG, AstraZeneca, GlaxoSmithKline plc, Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, LepuMedical Technology(Beijing)Co., Ltd., Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc., Microlife Corporation, Honsun, and others.
• Market Segmentation by Product Type: Inhalers [Dry Powder Inhaler, Metred Dose Inhaler, And Soft Mist Inhalers] And Nebulizers [Compressor Nebulizer, Ultrasonic Nebulizer, And Mesh Nebulizer]
• Market Segmentation By End-User: Hospitals & Clinics, Homecare Settings, And Other End-Users
• Market Segmentation by Geography: North America, Europe, Asia-Pacific, Rest of the World (Middle East, Africa, and South America)
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Table of Contents 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services